The obesity drug Wegovy showed broader health benefits than weight loss alone, improving physical fitness and symptoms of heart failure in patients with preserved ejection fraction, which is responsible for about half of all cases of heart failure, according to a study in The New England Journal of Medicine. The study highlights obesity’s contribution to heart failure, though experts believe that further investigation is required to isolate the impact of weight loss itself.
Full Story: The New York Times (8/25)